Peer-reviewedCC BY-NC 4.0The Oncologist
Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer
Related
- Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer
- Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer.
- Pharmacologic Targeting of ZNF281 Suppresses Metastatic Prostate Cancer Beyond Androgen Receptor Dependence
- Multi-Cycle Dosimetry of the Albumin-Binding Prostate-Specific Membrane Antigen Ligand [¹⁷⁷Lu]Ludotadipep in Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer with Adjusted Red Marrow Modeling.
- The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer
BibTeX
@article{nandakumar2026exceptional,
title = {{Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer}},
author = {Varun Nandakumar and Georges Gebrael and Neeraj Agarwal},
journal = {The Oncologist},
year = {2026},
month = oct,
doi = {10.1093/oncolo/oyag412},
url = {https://doi.org/10.1093/oncolo/oyag412},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer
AU - Varun Nandakumar
AU - Georges Gebrael
AU - Neeraj Agarwal
PY - 2026
DA - 2026/10/26
JO - The Oncologist
DO - 10.1093/oncolo/oyag412
UR - https://doi.org/10.1093/oncolo/oyag412
SN - 1083-7159
SN - 1549-490X
ER -